溶性泌尿酶等离子素激活受体 (suPAR) 作为糖尿病患者勃起功能障碍的生物标志物
Osman Erinc1, Ozgur Yilmaz1, Tacettin Yekta Kaya2
1Department of Internal Medicine, Kanuni Sultan Suleyman Training and Research Hospital, Istanbul 34303, Turkey.
Journal of clinical medicine
|June 26, 2025
概括
溶性泌尿酸酶等离子激素激活体受体 (suPAR) 水平升高与2型糖尿病男性的勃起功能障碍 (ED) 有关. 这表明suPAR可以作为早期生物标志物来检测糖尿病患者的ED.
科学领域:
- 内分泌学和新陈代谢学
- 心血管研究研究心血管研究
- 泌尿病学和雄性病学 泌尿和雄性病学
背景情况:
- 勃起功能障碍 (ED) 是糖尿病 (DM) 的普遍并发症,源于血管,神经和代谢问题.
- 溶性泌尿酸酶等离子体激活受体 (suPAR) 表明系统性炎症和内皮功能障碍,是ED发展的关键因素.
研究的目的:
- 在被诊断为2型糖尿病的患者中调查血清suPAR水平和ED之间的关联.
- 评估suPAR作为该患者群体中ED早期诊断生物标志物的潜力.
主要方法:
- 一项前性,横截面研究,涉及127名2型DM男性患者和46名健康对照.
- 使用国际勃起功能指数-5 (IIEF-5) 评估勃起功能.
- 使用ELISA量化血清suPAR水平,并进行统计分析,包括Kruskal-Wallis和ROC曲线分析.
主要成果:
- 与没有ED的糖尿病患者 (DM-NoED) 和对照患者 (p < 0.001) 相比,患有ED的糖尿病患者 (DMED) 的血清suPAR水平显著更高 (p < 0.001).
- 中位数的suPAR水平为107.9 pg/mL (对照组),130.3 pg/mL (DM-NoED) 和218.7 pg/mL (DMED) 的情况.
- ROC分析显示,在区分DMED与DM-NoED时,AUC为0.836,敏感度为87.5%,特异性为79.2%.
结论:
- 血清上升的suPAR水平与2型糖尿病男性的ED有显著的相关性,不论血糖控制或心血管风险因素如何.
- 在糖尿病患者中,suPAR作为早期检测和ED风险分层的生物标志物具有前途.
- 需要进一步的前性研究来验证suPAR在糖尿病ED治疗中的临床实用性.
相关概念视频
01:20Disorders of the Male Reproductive System
611
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
611
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
256
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
256